ArticleBMC cardiovascular disorders2025
Global burden of atrial fibrillation/flutter attributable to a high body mass index (HBMI) from 1990-2021.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrated biomarkers and cardiac phenotypes associated with atrial fibrillation: evidence from real-world hospital data.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThis study leveraged the Global Burden of Disease (GBD) database to assess sex- and region-specific trends in obesity-attributable atrial fibrillation and atrial flutter (AF/AFL) over the past three decades. We aimed to unravel temporal dynamics to inform evidence-based prevention and clinical management strategies.
methodsUsing 2021 GBD data, we evaluated the AF/AFL burden attributable to high body mass index (HBMI). Our analysis included deaths, age-standardized rates (ASR), disability-adjusted life years (DALYs), and estimated annual percentage changes (EAPC), stratified by age group, gender, Sociodemographic Index (SDI), and region. We also assessed health inequalities using the Gini coefficient and conducted hypothesis testing to examine relationships between mortality, disability rates, and gender from 1990 to 2021.
resultsIn 2021, HBMI-related AF/AFL caused 27,236 deaths and 724,573 DALYs globally. These figures represent increases of 66.7% and 272.5%, respectively, compared to 1990. The age-standardized mortality rate (ASMR) and DALY rate rose by 66.7% and 67.8%. Nearly half of the disease burden occurred in high and upper-middle SDI regions; however, other SDI regions are experiencing a rapid increase in burden. Notably, elderly women aged 65 + bore the highest disease burden. The Gini index for DALY rates declined from 0.45 in 1990 to 0.35 in 2020, indicating reduced health inequality. While women had a higher overall burden, men exhibited faster growth in mortality and disability rates. Over the past 30 years, the EAPC for DALYs and mortality in men was 1.76 and 1.85 times higher, respectively, than in women. Critically, in high-SDI regions, men’s absolute disability burden and rates have surpassed women’s across all age groups.
conclusionDisparities in the HBMI-attributable AF/AFL burden (HAB) across sociodemographic strata have narrowed significantly over the past three decades, reflecting progressive mitigation of structural health inequities. Economic advancement propagates the HAB across the development spectrum, and temporal analysis confirms this trajectory. The current burden profile observed in high-SDI regions suggests the future epidemiological path for lower-SDI settings. GBD projections indicate an impending reversal of the AF/AFL burden sex differential. Accelerating male-predominant obesity trends are poised to drive disproportionate burden escalation in coming decades. Targeted screening and early therapeutic intervention in young obese cohorts may mitigate future burden escalation among aging populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.